Aligos Therapeutics Presents Positive Data at the EASL Congress 2025

Core Insights - Aligos Therapeutics, Inc. announced positive data from eight presentations at the EASL Congress 2025, highlighting advancements in therapies for liver and viral diseases [1][2] Group 1: ALG-000184 for Chronic Hepatitis B - The 96-week data from the monotherapy cohort receiving 300 mg ALG-000184 showed that all subjects in both HBeAg+ and HBeAg- cohorts achieved HBV DNA viral suppression below the lower limit of quantification (LLOQ) [2][3] - In HBeAg+ subjects, 60% achieved HBV DNA < LLOQ at Week 48, which increased to 100% at Week 96, with HBV DNA levels declining to < LLOQ in 5 of 9 subjects [3] - All HBeAg- subjects (100%) experienced rapid HBV DNA suppression by Week 24, maintaining suppression for up to 96 weeks [4] - No viral breakthrough was observed in any subjects receiving ALG-000184 for up to 96 weeks, and no known resistant mutations were identified [5] Group 2: ALG-055009 for Metabolic Dysfunction-Associated Steatohepatitis (MASH) - ALG-055009 demonstrated significant reductions in liver fat content, with placebo-adjusted median relative reductions up to 46.2% at Week 12 [8] - The treatment was well-tolerated, with gastrointestinal-related adverse events similar to placebo [8] - Statistically significant improvements in atherogenic lipids were observed, indicating potential cardiovascular benefits alongside liver fat reduction [9][10] Group 3: Presentation Details - Key presentations included data on ALG-000184's antiviral effects and safety, as well as ALG-055009's impact on liver fat and lipid profiles [10][11][12] - Notable presenters included experts from the University of Hong Kong and Southern Medical University, showcasing the clinical significance of the findings [10][11] Group 4: Company Overview - Aligos Therapeutics is focused on developing best-in-class therapies for liver and viral diseases, leveraging its R&D expertise to address high unmet medical needs [15]